Commitments and Contingencies |
12 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Commitments and Contingencies [Abstract] | |
| Commitments and Contingencies | Note 18. Commitments and Contingencies Ironwood Pharmaceuticals, Inc. In January 2012, the Company entered into a research and license agreement with Ironwood Pharmaceuticals, Inc. ("Ironwood") pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to the Company. The sole obligation to Ironwood is to pay Ironwood low single digit royalties on the net sales of BNC210, if commercialized. It is not practicable to estimate the future payments of any such royalties that may arise due to the stage of development of BNC210. Severance Obligation The Company has a remaining liability in relation to severance agreements with certain employees, including Dr. Spyros Papapetropoulos, for severance pay of approximately $0.1 million at June 30, 2026 and has included said amount in the restructuring liability. |